Speciality Medical Dialogues
    • facebook
    • twitter
    Login Register
    • facebook
    • twitter
    Login Register
    • Medical Dialogues
    • Education Dialogues
    • Business Dialogues
    • Medical Jobs
    • Medical Matrimony
    • MD Brand Connect
    Speciality Medical Dialogues
    • Editorial
    • News
        • Anesthesiology
        • Cancer
        • Cardiac Sciences
        • Critical Care
        • Dentistry
        • Dermatology
        • Diabetes and Endo
        • Diagnostics
        • ENT
        • Featured Research
        • Gastroenterology
        • Geriatrics
        • Medicine
        • Nephrology
        • Neurosciences
        • Nursing
        • Obs and Gynae
        • Ophthalmology
        • Orthopaedics
        • Paediatrics
        • Parmedics
        • Pharmacy
        • Psychiatry
        • Pulmonology
        • Radiology
        • Surgery
        • Urology
    • Practice Guidelines
        • Anesthesiology Guidelines
        • Cancer Guidelines
        • Cardiac Sciences Guidelines
        • Critical Care Guidelines
        • Dentistry Guidelines
        • Dermatology Guidelines
        • Diabetes and Endo Guidelines
        • Diagnostics Guidelines
        • ENT Guidelines
        • Featured Practice Guidelines
        • Gastroenterology Guidelines
        • Geriatrics Guidelines
        • Medicine Guidelines
        • Nephrology Guidelines
        • Neurosciences Guidelines
        • Obs and Gynae Guidelines
        • Ophthalmology Guidelines
        • Orthopaedics Guidelines
        • Paediatrics Guidelines
        • Psychiatry Guidelines
        • Pulmonology Guidelines
        • Radiology Guidelines
        • Surgery Guidelines
        • Urology Guidelines
    LoginRegister
    Speciality Medical Dialogues
    LoginRegister
    • Home
    • Editorial
    • News
      • Anesthesiology
      • Cancer
      • Cardiac Sciences
      • Critical Care
      • Dentistry
      • Dermatology
      • Diabetes and Endo
      • Diagnostics
      • ENT
      • Featured Research
      • Gastroenterology
      • Geriatrics
      • Medicine
      • Nephrology
      • Neurosciences
      • Nursing
      • Obs and Gynae
      • Ophthalmology
      • Orthopaedics
      • Paediatrics
      • Parmedics
      • Pharmacy
      • Psychiatry
      • Pulmonology
      • Radiology
      • Surgery
      • Urology
    • Practice Guidelines
      • Anesthesiology Guidelines
      • Cancer Guidelines
      • Cardiac Sciences Guidelines
      • Critical Care Guidelines
      • Dentistry Guidelines
      • Dermatology Guidelines
      • Diabetes and Endo Guidelines
      • Diagnostics Guidelines
      • ENT Guidelines
      • Featured Practice Guidelines
      • Gastroenterology Guidelines
      • Geriatrics Guidelines
      • Medicine Guidelines
      • Nephrology Guidelines
      • Neurosciences Guidelines
      • Obs and Gynae Guidelines
      • Ophthalmology Guidelines
      • Orthopaedics Guidelines
      • Paediatrics Guidelines
      • Psychiatry Guidelines
      • Pulmonology Guidelines
      • Radiology Guidelines
      • Surgery Guidelines
      • Urology Guidelines
    • Home
    • News
    • Gastroenterology
    • Sodium polystyrene...

    Sodium polystyrene sulfonate used for hyperkalemia in CKD increases severe GI complications risk

    Written by Medha Baranwal Baranwal Published On 2019-09-01T19:30:40+05:30  |  Updated On 1 Sept 2019 7:30 PM IST
    Sodium polystyrene sulfonate used for hyperkalemia in CKD increases severe GI complications risk

    Delhi: Sodium polystyrene sulfonate (SPS) initiation in patients with advanced chronic kidney disease (CKD) increases the risk for severe gastrointestinal (GI) complications, finds a recent study published in the Nephrology Dialysis Transplantation journal.


    SPS is commonly prescribed for the treatment of hyperkalemia -- a common and potentially life-threatening complication of advanced CKD. Data on the safety of SPS are scarce and ambiguous despite its long-standing clinical use for CKD patients.


    Paola Laureati, Karolinska Institutet, Stockholm, Sweden, and colleagues set out to systematically examine SPS use and GI safety in a large Swedish representative cohort of nephrologist-referred persons with CKD.


    The researchers undertook a study of 19,530 nephrology-referred adults with incident CKD Stage 4+ in Sweden from 2006–2016 and with no previous SPS use. During follow up patterns of use and adverse events associated with SPS initiation was studied. Patterns of SPS use were defined by the chronicity of treatment and by prescribed dose.


    Of 19,530 patients 3690 patients initiated SPS, including 59% who took SPS chronically (3 mean dispensations of 450 g each per year). The majority (85%) were prescribed lower dosages than specified on the product label.


    Also Read: Roxadustat safe and effective for anemia correction in non-dialysis CKD patients


    Key findings include:




    • During follow-up, 202 severe and 1149 minor GI events were recorded.

    • SPS initiation was associated with a higher incidence of severe adverse events, particularly in those receiving per label doses [1.54 (1.09–2.17)] and mainly attributed to ulcers and perforations.

    • SPS initiation was also associated with a higher incidence of minor GI events, regardless of dose, and mainly accounted for by de novo dispensation of laxatives.


    Also Read: Ferric Citrate effective in Hyperphosphatemia and Anemia in iron deficient CKD patients


    A recent study published in the JAMA Internal Medicine similarly found that the use of sodium polystyrene sulfonate is associated with a higher risk of hospitalization for serious adverse GI events.


    The JAMA study including more than 27,000 SPS users similarly found that 0.2% experienced intestinal ischemia or thrombosis, ulceration or perforation, or resection or ostomy.


    "To conclude, this real-world evidence analysis shows that SPS is frequently used by persons with advanced CKD/ESKD chronically and at lower dosages than specified on the product label. Compared with non-use, we observed an increased relative risk of the combined endpoint of intestinal ischaemia, thrombosis or ulceration/perforation for SPS use. In addition, SPS use was associated with a higher rate of laxative dispensations. These associations were more evident in patients prescribed per label SPS dosages," wrote Dr. Laureati and colleagues.


    To read the complete study follow the link: https://doi.org/10.1093/ndt/gfz150
    chronic kidney diseaseCKDgastrointestinal complicationsGI complicationsGI eventshyperkalemiaMedical newsNephrology Dialysis TransplantationPaola Laureatirecent medical newsSodium Polystyrene SulfonateSPS

    Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

    Medha Baranwal Baranwal
    Medha Baranwal Baranwal
      Show Full Article
      Next Story
      Similar Posts
      NO DATA FOUND

      • Email: info@medicaldialogues.in
      • Phone: 011 - 4372 0751

      Website Last Updated On : 12 Oct 2022 7:06 AM GMT
      Company
      • About Us
      • Contact Us
      • Our Team
      • Reach our Editor
      • Feedback
      • Submit Article
      Ads & Legal
      • Advertise
      • Advertise Policy
      • Terms and Conditions
      • Privacy Policy
      • Editorial Policy
      • Comments Policy
      • Disclamier
      Medical Dialogues is health news portal designed to update medical and healthcare professionals but does not limit/block other interested parties from accessing our general health content. The health content on Medical Dialogues and its subdomains is created and/or edited by our expert team, that includes doctors, healthcare researchers and scientific writers, who review all medical information to keep them in line with the latest evidence-based medical information and accepted health guidelines by established medical organisations of the world.

      Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription.Use of this site is subject to our terms of use, privacy policy, advertisement policy. You can check out disclaimers here. © 2025 Minerva Medical Treatment Pvt Ltd

      © 2025 - Medical Dialogues. All Rights Reserved.
      Powered By: Hocalwire
      X
      We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok